The week in pharma: action, reaction and insight - week to November 12, 2021
By Barbara Obstoj-Cardwell
Significant news last week including UK Pharma major GlaxoSmithKline releasing positive new data on its daprodustat as a new option for anemia in kidney disease. Deal-making developments featured Pfizer entering an agreement that could cost it up to $1.2 billion to gain certain rights to Biohaven Pharma’s migraine drug Nurtec. Also, Roche subsidiary Genentech inked a license and research collaboration with US start-up Novome Biotechnologies on inflammatory bowel disease (IBD). Meantime, Japan’s Kyowa Kirin gained a positive recommendation for its rare blood cancer drug Poteligeo from the UK’ health technology assessor the NICE. Additionally, health care giant Johnson & Johnson surprised markets, with the announcement that it is splitting out its Consumer Health business into a separate publicly-traded company.
GlaxoSmithKline’s daprodustat delivers
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze